Biotechnology company TrippBio said on Thursday that it plans to develop a groundbreaking patent-pending repurposed USD FDA approved drug called TD213 for viral infections caused by COVID-19.
The company said TD213 works by blocking the SARS-CoV-2 virus' replication and the associated acute inflammatory response to the infection.
Additioanally, Dr Moti N Ramgopal of Midway Immunology and Research Center launched the investigator-initiated study (IIS) to assess the efficacy of the company's TD213 in treating patients with confirmed mild - moderate COVD-19 infections. The final patient was enrolled in this proof of concept (POC) study and all participants are progressing through the protocol designated testing and follow-up visits.
In conjunction, the company seeks support of the worldwide community to continue into the next phase of testing and will use the capital from ongoing equity crowdfunding to extend clinical trials needed for the global regulatory approval and commercialization of TD213.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT